Glaukos Corporation (GKOS)

NYQ – Real Time Price. Currency in USD

136.36

+0.99 (0.73%)

At close: May 12, 2026, 4:00 PM EDT

12.05.2026

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

30.04.2026

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.

30.04.2026

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

30.04.2026

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

29.04.2026

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.

29.04.2026

Glaukos Announces First Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.

16.04.2026

Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy

GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.

Videos

No Data

There is no data to display

Press releases

29.04.2026

Glaukos Announces First Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.

16.04.2026

Glaukos Announces the Release of its 2025 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website here. “I am prou.

15.04.2026

Glaukos Receives Permanent J-code for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease.

19.03.2026

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

Glaukos Corporation (GKOS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Glaukos Corporation (GKOS)

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy

Videos

No Data

Press releases

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy

Videos

No Data

Press releases

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Search stocks

Glaukos Corporation (GKOS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Glaukos Corporation (GKOS)

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy

Videos

No Data

Press releases

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy

Videos

No Data

Press releases

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care